Coronavirus solutions

With its two complementary platform technologies Amplidiag® and Novodiag®, Mobidiag has the capacity to meet the needs of clinical laboratories and multiple healthcare settings. These platforms currently on the market combine high quality and affordable costs, allowing widespread use both in mass screening and on-demand highly targeted or syndromic tests for various indications. The extremely versatile product offer, the flexibility of the technologies used, and the expertise of the Mobidiag team allow great responsiveness in the development of new products in emergency situations. The solution that Mobidiag is offering in the case of the coronavirus pandemic is a perfect example.

The first available test is the Anti-SARS-CoV-2 Rapid Test. This immunoassay allows detection of IgG and IgM from human serum, whole blood or plasma in about 15 minutes. Manufactured by Autobio Diagnostics, Mobidiag key partner and leading clinical diagnostics company in the Chinese the market, the Anti-SARS-CoV-2 test is now available through Mobidiag sales channels as well as our local distributors (except in Portugal, the Netherlands and Ukraine).

Currently, 2 complementary molecular tests are being developed by Mobidiag: Novodiag® COVID-19 and Amplidiag® COVID-19.

Choose the right coronavirus test based on your needs:

Anti-SARS-CoV-2 Rapid Test* Novodiag® COVID-19 Amplidiag® COVID-19
Technology Lateral flow PCR PCR
Reference RTA0202 NVD-CV-012 AD-COV-864
Packaging 20 tests 1 kit = 12 cartridges 9x96 tests
Sample type Human serum, plasma or whole blood Nasopharyngeal swab Nasopharyngeal swab
Targets SARS-CoV-2 antibodies (IgM and IgG) SARS-CoV-2 (orf1ab)
SARS-CoV-2 (N)
SARS-CoV-2 (orf1ab)
SARS-CoV-2 (N)
Benefits Fast (15min)
Easy to use
Specificity
Can detect previous infections
Fast (<1h)
Sensitivity
Specificity
Small volumes, on demand
Low hands-on time (<5min)
Detection at early infection stage
Easy to use
Ensure safety of healthcare professionals
Sensitivity
Specificity
Large volumes
Detection at early infection stage
Availability CE-IVD Under development Under development

*Manufactured by Autobio Diagnostics, Mobidiag key partner and market leading Chinese clinical diagnostics company

Key Advantages

- A test for all sample volumes
- Choose from automated, semi-automated or manual workflow based on your available equipment
- Detect current or past infections

Contact sales@mobidiag.com or fill in the form below for more information and orders.

 

Dedicated tests

Anti-SARS-CoV-2 Rapid Test

CE-IVD. For in vitro diagnostic use.

The immunoassay Anti-SARS-CoV-2 Rapid Test (manufactured by Autobio Diagnostics) is based on a colloidal gold method for the rapid, qualitative determination of Anti-SARS-CoV-2 (IgG/IgM antibodies of Severe Acute Respiratory Syndrome Coronavirus 2) in human serum, plasma or whole blood.
This assay is based upon one-step capture method. It contains a membrane, which is pre-coated with two mouse anti-human monoclonal antibodies (anti-IgG and anti-IgM) on two separated test lines.

Contact sales@mobidiag.com or fill in the form below for more information and orders.

Mobidiag - Novodiag kasetti

Novodiag® COVID-19 (under dev.)

Under development. The upcoming Novodiag® COVID-19 test will operate using the rapid ‘sample-in, result-out’ Novodiag® system, allowing the rapid detection of novel coronavirus in less than 1 hour. This fully automated solution protects laboratory staff from potential contamination. With its user-friendly nature, the Novodiag® COVID-19 solution can be delivered to and will be targeted for use in high risk and hard to reach areas without the need for highly trained personnel. This qualitative real-time PCR test will support decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.
Contact sales@mobidiag.com or fill in the form below for more information and orders.

Amplidiag® COVID-19 (under dev.)

Under development.

The upcoming Amplidiag® COVID-19 test allows the rapid detection of novel coronavirus. By allowing rapid and reliable detection of this novel coronavirus, this qualitative real-time PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.

Contact sales@mobidiag.com or fill in the form below for more information and orders.